CGEM stock forecast
Our latest prediction for Cullinan Oncology Inc's stock price was made on the Oct. 15, 2021 when the stock price was at 25.00$.
In the short term (2weeks), CGEM's stock price should underperform the market by -2.78%. During that period the price should oscillate between -10.66% and +11.18%.
In the medium term (3months), CGEM's stock price should underperform the market by -3.10%. During that period the price should oscillate between -39.19% and +29.39%.Get email alerts
Create a solid portfolio with CGEM
About Cullinan Oncology Inc
Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.
At the moment the company generates 19M USD in revenues.
On its last earning announcement, the company reported a loss of -1.24$ per share.
The book value per share is 5.61$
Three months stock forecastOct. 15, 2021
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|